A Glimpse Into The Expert Outlook On Globus Medical Through 8 Analysts
Portfolio Pulse from Benzinga Insights
Eight analysts have provided ratings for Globus Medical (NYSE:GMED) over the past three months, with a mix of bullish and indifferent sentiments. The average 12-month price target has increased by 9.19% to $78.62. Recent analyst actions include several rating upgrades and increased price targets, reflecting positive sentiment. Despite strong revenue growth, Globus Medical faces challenges with below-average net margins, ROE, and ROA.
August 28, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Globus Medical has received mixed analyst ratings, with a recent increase in the average price target to $78.62, indicating positive sentiment. However, the company faces challenges with profitability and asset efficiency despite strong revenue growth.
The increase in the average price target and several rating upgrades suggest positive short-term sentiment among analysts. However, the company's financial metrics like net margin, ROE, and ROA are below industry averages, which could limit upside potential. The strong revenue growth is a positive indicator, but the challenges in profitability and asset efficiency need to be addressed for sustained performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100